Immunocore Limited
90 Park Drive
Milton Park
Abingdon
Oxon
OX14 4RY
United Kingdom
Tel: 44-0-1235-438600
Fax: 44-0-1235-438601
Website: http://www.immunocore.com/
116 articles about Immunocore Limited
-
Uveal melanoma is a rare and aggressive form of melanoma. It primarily affects the eye. There are no currently accepted optimal management regimens or treatments.
-
Immunocore to Spotlight ImmTAC® Platform Research at 2019 SITC Annual Conference
10/31/2019
Analyses of tebentafusp data provide further insight into platform’s mechanism of action, potential link to clinical activity in uveal melanoma
-
Immunocore and Pulse Infoframe, Inc. Partner with Leading Academic Institutions to Launch First Global Patient Registry for Uveal Melanoma
7/18/2019
Patient-reported data will help inform research in rare form of eye cancer
-
New Biomarker Research Builds Further Understanding of Tebentafusp (IMCgp100) Mechanism of Action, Link to Clinical Activity in Advanced Melanoma
6/3/2019
Monotherapy treatment with the first-in-class ImmTAC® molecule tebentafusp (IMCgp100) induced an immunologically potent response in patients with advanced uveal and cutaneous melanoma, according to new data presented today by Immunocore Limited at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting.
-
Immunocore to Present New Tebentafusp (IMCgp100) Data in Advanced Melanoma at Upcoming 2019 ASCO Annual Meeting
5/16/2019
Immunocore Limited, a leading T cell receptor (TCR) biotechnology company, will present new mechanism of action data in advanced uveal and cutaneous melanoma from the tebentafusp clinical research programme at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago on 3 June 2019.
-
BioSpace Movers and Shakers: May 10
5/10/2019
Pharma and biotech companies strengthen their leadership teams with new hires at Immunocore, Eisai, Kyn, Bicycle, and more. -
Immunocore appoints Dr Mohammed Dar as Head of Clinical Development and Chief Medical Officer
5/8/2019
Immunocore Limited, a leading T cell receptor (TCR) biotechnology company, today announces that Dr Mohammed Dar has been appointed as Head of Clinical Development and Chief Medical Officer, effective April 16, 2019.
-
Immunocore’s Lead Asset Tebentafusp Gains Fast Track Designation for Metastatic Uveal Melanoma
4/3/2019
Immunocore Limited announces that the U.S. Food and Drug Administration has granted Fast Track Designation for its development program, the investigation of tebentafusp for the treatment of patients who are HLA-A*0201-positive with previously untreated, metastatic uveal melanoma.
-
Immunocore Names David Berman as Head of R&D
1/15/2019
Leading figure in immuno-oncology strengthens Immunocore’s senior leadership team
-
BioSpace Movers and Shakers: Jan. 11
1/11/2019
Biopharma companies strengthen the leadership teams during the annual J.P. Morgan Healthcare Conference. -
Immunocore and Genentech Dig into Immuno-Oncology in Solid Tumors With Expanded Research Deal
11/19/2018
This deal is an expansion of an existing discovery collaboration. Immunocore will head the first-in-human clinical trial of the drug alone and in combination with Genentech’s checkpoint inhibitor Tecentriq (atezolizumab). -
BioSpace Movers and Shakers - Oct. 22
10/22/2018
Execs at Novo Nordisk, AbbVie, and more made moves this week. Here's a roundup of those changes. -
Immunocore strengthens IP position in the field of TCR-based therapeutics
9/10/2018
Notice of Allowance received from US patent and trademark office relating to ImmTAC® platform
-
Immunocore Announces Start of Phase I ImmTAC® Study in Patients with Solid Tumours
8/20/2018
Immunocore Limited, a leading T Cell Receptor (TCR) biotechnology company, focused on delivering first-in-class biological therapies that have the potential to transform the lives of people with serious diseases, today announces that it has dosed the first patient in a Phase I study, part of an ongoing collaboration with GlaxoSmithKline (GSK).
-
Tmunity Appoints Christina Coughlin, MD, PhD, as Chief Medical Officer and Executive Vice President
7/10/2018
Tmunity Therapeutics, Inc. today announced the appointment of Christina Coughlin, MD, PhD, as Chief Medical Officer and Executive Vice President.
-
New IMCgp100-102 Data Show Durable Response and Robust Overall Survival Rate in Patients with Metastatic Uveal Melanoma
6/4/2018
Patients with metastatic uveal melanoma (mUM) treated with IMCgp100 continued to experience a durable tumour response with a median follow up of 19.1 months, without yet reaching median overall survival (OS), according to new Phase I research to be presented today at the American Society of Clinical Oncology (ASCO) Annual Meeting
-
Immunocore to Present New Data from IMCgp100-102 Trial in Metastatic Uveal Melanoma at 2018 ASCO Annual Meeting
5/22/2018
Immunocore Limited, a leading T cell receptor (TCR) company focused on delivering first-in-class biological therapies that have the potential to transform lives, today announces that new data from its phase I/II dose escalation trial of its wholly-owned, lead programme, IMCgp100, in metastatic uveal melanoma (mUM) will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago on 4 June 2018.
-
Leading Biotech Immunocore Expands to the Oxford Science Park
12/11/2017
Immunocore Limited, the world’s leading TCR company focused on delivering first-in-class biological therapies that transform lives, has taken laboratory and office space at The Oxford Science Park.
-
Bill & Melinda Gates Foundation Sinks $40 Million Into Immunocore for Infectious Disease R&D
9/19/2017
-
Immunocore Presents Positive Monotherapy Data In Uveal Melanoma At The Society For Melanoma Research (SMR) 2016 Congress
11/9/2016